Curis AnnouncesFDA Removes Partial Clinical Hold On TakeAim Leukemia Study RP2D Established At 300 mg BID
Portfolio Pulse from Benzinga Newsdesk
The FDA has lifted the partial clinical hold on Curis' TakeAim Leukemia Study, with the recommended phase 2 dose (RP2D) established at 300 mg twice daily. This could potentially accelerate the development and approval process for Curis' leukemia treatment.
July 06, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA's decision to lift the partial clinical hold on Curis' TakeAim Leukemia Study could potentially accelerate the development and approval process for Curis' leukemia treatment, which may positively impact the company's stock in the short term.
The lifting of the FDA's partial clinical hold means that Curis can proceed with its leukemia study without restrictions. This could potentially speed up the development and approval process for its leukemia treatment, which could lead to increased revenues and a positive impact on its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100